Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Poulam Patel"'
Autor:
Miranda Payne, Sarah Danson, Satish Kumar, Poulam Patel, Heather Shaw, Robert Miller, Martin Highley, Clare Barlow, Fayaz Master, Lindy Durrant
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/f3b889539be64e0885c70c6b8c662d93
Autor:
Wei Sun, Yu Xu, JiLong Yang, ZhiChao Liao, Tao Li, Kai Huang, Poulam Patel, WangJun Yan, Yong Chen
Publikováno v:
Cancer Communications, Vol 40, Iss 11, Pp 586-597 (2020)
Abstract Background Whether non‐sentinel lymph node (SLN)‐positive melanoma patients can benefit from completion lymph node dissection (CLND) is still unclear. The current study was performed to identify the prognostic role of non‐SLN status in
Externí odkaz:
https://doaj.org/article/852e734b54cb46cba46f646b8b74e97a
Autor:
Michelle Wilson, Naveen S Vasudev, Grant D Stewart, Adebanji Adeyoju, Jon Cartledge, Michael Kimuli, Shibendra Datta, Damian Hanbury, David Hrouda, Grenville Oades, Poulam Patel, Naeem Soomro, Mark Sullivan, Jeff Webster, Peter J Selby, Rosamonde E Banks
Publikováno v:
BMJ Open, Vol 10, Iss 5 (2020)
Objectives To describe the frequency and nature of symptoms in patients presenting with suspected renal cell carcinoma (RCC) and examine their reliability in achieving early diagnosis.Design Multicentre prospective observational cohort study.Setting
Externí odkaz:
https://doaj.org/article/6cfcf49e402e4693a956dc28fe5252e7
Autor:
Cristina Suárez, James M.G. Larkin, Poulam Patel, Begoña P. Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Ryan Hartmaier, Aleksandra Markovets, Aaron Prendergast, Bernadett Szabados, Kelly Mousa, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:2493-2502
PURPOSE Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) and programmed cell death ligand-1 (PD-L1) inhibition i
Autor:
Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, Marios Decatris, Carys Thomas, Joanna Gale, James McAleer, Alison Clayton, Ekaterini Boleti, Thomas Geldart, Santhanam Sundar, Jason Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, Rajaguru Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, Nicholas Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, Sharon Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry Taylor, Christos Mikropoulos, Martin Highley, Dakshinamoorthy Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, Urmila Barthakur, Erica Beaumont, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti
Publikováno v:
STAR Investigators, Brown, J E, Royle, K-L, Gregory, W, Ralph, C, Maraveyas, A, Din, O, Eisen, T, Nathan, P, Powles, T, Griffiths, R, Jones, R, Vasudev, N, Wheater, M, Hamid, A, Waddell, T, McMenemin, R, Patel, P, Larkin, J, Faust, G, Martin, A, Swain, J, Bestall, J, McCabe, C, Meads, D, Goh, V, Min Wah, T, Brown, J, Hewison, J, Selby, P & Collinson, F 2023, ' Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial ', Lancet Oncology, vol. 24, no. 3, pp. 213-227 . https://doi.org/10.1016/S1470-2045(22)00793-8
Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional conti
Autor:
Francesca Jackson-Spence, Charlotte Ackerman, Bernadett Szabados, Charlotte Toms, Agne Jovaisaite, Rachel Gunnell, Cristina Suárez, James Larkin, Poulam Patel, Begoña Pérez Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona C. Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Aleksandra Markovets, Ryan James Hartmaier, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:725-725
725 Background: The characterisation of DNA alternations in papillary renal cancer (PRC) is unclear. The CALYPSO trial (NCT02819596) prospectively evaluated combination therapy of savolitinib (MET inhibitor) and durvalumab (PD-L1 inhibitor) in PRC. T
Autor:
Kate I. Glennon, Naveen S. Vasudev, Ghislaine Scelo, Michelle Wilson, Louis Letourneau, Robert Eveleigh, Nazanin Nourbehesht, Madeleine Arseneault, Antoine Paccard, Lars Egevad, Juris Viksna, Edgars Celms, Sharon M. Jackson, Behnoush Abedi-Ardekani, Anne Y. Warren, Peter J. Selby, Sebastian Trainor, Michael Kimuli, Naeem Soomro, Adebanji Adeyoju, Poulam Patel, Magdalena B. Wozniak, Ivana Holcatova, Antonin Brisuda, Vladimir Janout, Estelle Chanudet, David Zaridze, Anush Moukeria, Oxana Shangina, Lenka Foretova, Marie Navratilova, Dana Mates, Viorel Jinga, Ljiljana Bogdanovic, Bozidar Kovacevic, Anne Cambon-Thomsen, Guillaume Bourque, Alvis Brazma, Jörg Tost, Paul Brennan, Mark Lathrop, Yasser Riazalhosseini, Rosamonde E. Banks
Publikováno v:
Cancer Research. 82:LB113-LB113
Renal cell carcinomas (RCC) are characterized by their heterogenous clinical outcomes, and due to their indeterminate behavior and the absence of routine biomarkers, it is difficult to identify patients who are at high-risk for relapse after curative
Publikováno v:
Cochrane Database Syst Rev
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To critically appraise the safety data of immunotherapy by identifying rates of toxicities focusing on neurologic adverse events. To compare the survival outcomes
Autor:
Judith Christian, Poulam Patel, Claire Diver, Ananth Sivanandan, Luis Aznar-GArcia, Pui-Shan Tang, Micheal O'Cathail
BACKGROUND The National Health Service Long Term Plan details plans to make digital interactions available to all patients in 5 years. Teleconsultations can improve access to specialist services; however, there is a lack of evidence for the use of te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90f261bad909028c381d00fe97a8eb4c
https://doi.org/10.2196/preprints.15598
https://doi.org/10.2196/preprints.15598
BACKGROUND The National Health Service (NHS) Long-Term Plan has set out a vision of enabling patients to access digital interactions with health care professionals within 5 years, including by video link. OBJECTIVE This review aimed to examine the ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d1f8e5fbe023a194c4fc4be8f79fc2f
https://doi.org/10.2196/preprints.15380
https://doi.org/10.2196/preprints.15380